Raising the consciousness for identifying and controlling viral STDs: Fears and frustrations - Thomas Parran Award Lecture

Sexually Transmitted Diseases

Volumn 25, Issue 2, 1998, Pages 58-69

  Corey, Lawrence ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; HERPES VACCINE;

CONFERENCE PAPER; COST BENEFIT ANALYSIS; GENITAL HERPES; HERPES SIMPLEX VIRUS; HUMAN; INFECTION CONTROL; MEDICAL RESEARCH; PROBLEM SOLVING; SERODIAGNOSIS; SEXUALLY TRANSMITTED DISEASE; VIRUS INFECTION;

ACYCLOVIR; AWARDS AND PRIZES; HEALTH PROMOTION; HUMANS; MASS SCREENING; SEROLOGIC TESTS; SEXUALLY TRANSMITTED DISEASES, VIRAL; UNITED STATES; VIROLOGY;

EID: 0031888630     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-199802000-00002     Document Type: Conference Paper

References (122)

1. Corey L, Rubin RJ, Hattwick MAW, Noble GR, Cassidy E. A nationwide out-break of Reye's syndrome: Its epidemiologic relationship to influenza B. Am J Med 1976; 61:615-626.
2. Corey L, Rubin RJ, Thompson R, et al. Influenza B-associated Reye's syndrome. Incidence in Michigan and potential for prevention. J Infect Dis 1977; 133:398-407.
3. Corey L, Rubin RJ, Bergman D, Gregg MB. Diagnostic criteria for influenza B-associated Reye's syndrome: Clinical vs. pathologic criteria. Pediatrics 1977; 60:702-708.
4. Rattray MD, Corey L, Reeves WC, Vontver LA, Holmes KK. Recurrent genital herpes among women: symptomatic vs. asymptomatic viral shedding. Brit J Vener Dis 1978; 54:262-265.
5. Corey L, Holmes KK. Transmission of hepatitis A in homosexual men: Incidence and mechanism. N Engl J Med 1980; 302:435-138.
6. Corey L, Reeves WC, Holmes KK. Cellular immune response in genital herpes simplex virus infection. N Engl J Med 1978; 299:986-991.
7. Corey L, Stamm W, Feorino PJ, et al. HBsAg negative hepatitis in a hemodialysis unit. Relation to Epstein-Barr virus. N Engl J Med 1975; 293:1273-1278.
8. Rubin RJ, Noble GR, Corey L, et al. Live attenuated influenza A/England/42/72 (H3N2) vaccine. A field trial. J Infect Dis 1976; 133:613-620.
9. Adams HG, Benson EA, Alexander ER, et al: Genital herpetic infection in men and women: clinical course and effect of topical application of adenine arabinoside. J Infect Dis 1976; 133(suppl): A151-A159.
10. Becker TM, Blount JH, German MF. Genital herpes in private practice in the United States, 1966-1981. JAMA 1985; 253:1601-1603.
11. Quinn TC, Corey L, Chaffee RG, Schuffler MD, Brancato FP, Holmes KK. The etiology of anorectal infections in homosexual men. Am J Med 1981; 71:395-406.
12. Goodell SE, Quinn TC, Mkrtichian E, Schuffler MD, Holmes KK, Corey L. Herpes simplex virus proctitis in homosexual men. N Engl J Med 1983; 308:868-871.
13. Corey L, Knox SR, Perkins RL, Noble RC, Lee RV, Dans PE. IDSA Dialogue: Countering the epidemic of sexually transmitted diseases: A call to action. J Infec Dis 1982; 145:422-426.
14. Battling an elusive invader. Time Magazine 1982; 20(5).
15. Corey L. The diagnosis and treatment of genital herpes. JAMA 1982; 248:1041-1049.
16. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infection: Clinical manifestations, course and complications. Ann Intern Med 1983; 98:958-972.
17. Corey L, Holmes KK. Genital herpes simplex virus infection: Current concepts in diagnosis, therapy and prevention. Ann Intern Med 1983; 98:973-983.
18. Sullivan-Bolyai J, Hull HF, Wilson C, Corey L. Neonatal herpes simplex virus infections in King County, Washington. JAMA 1983; 250:3059-3062.
19. Sullivan-Bolyai JZ, Fife KH, Jacobs RF, Miller Z, Corey L. Disseminated neonatal herpes simplex virus type 1 from a maternal breast lesion. Pediatrics 1983; 71(3):455-457.
20. Brown ZA, Vontver LA, Benedetti J, et al. Effects on the infants of first episode genital herpes during pregnancy. N Engl J Med 1987; 317:1247-1251.
21. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337:509-515.
22. Corey L. Chemotherapy of herpes simplex virus infections. In: Isselbacher K, et al, eds. Harrison's Principles of Internal Medicine, Update III. New York: McGraw-Hill, 1982: 31-52.
23. Sabin AB: Misery of recurrent herpes: What to do. N Engl J Med 1975; 293:986-987.
24. Corey L, Reeves WC, Chiang WT, et al: Ineffectiveness of topical ether for the treatment of genital herpes simplex virus infection. N Engl J Med 1978; 299:237-239.
25. Knox SR, Corey L, Blough HA, Lerner AM. Historical findings in subjects from a high socioeconomic group who have genital infections with herpes simplex virus. Sex Trans Dis 1982; 9:15-20.
26. Catotti D, Clarke P, Catoe K. Herpes revisited: Still a cause of concern. Sex Trans Dis 1993; 209:77-80.
27. Elion GB, Furman PA, Fyfe JA, et al. Selectivity of Acyclovir on an antiherpetic agent 9-(2- hydroxyethoynethyl)-gurmal. Proc Natl Acad Sci 1992; 74:5716-5720.
28. Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. A trial of topical acyclovir in genital herpes simplex infections. N Engl J Med 1982; 306:1313-1319.
29. Corey L, Fife KH, Benedetti JK, et al. Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med 1983; 98:914-921.
30. Ashley RL, Corey L. Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus. J Clin Invest 1984; 73:681-688.
31. Corey L, Benedetti J, Critchlow C, et al. Treatment of primary first episode genital HSV infections with acyclovir: Results of topical, intravenous and oral therapy. J Antimicrob Chemother 1983; 12(B):79-88.
32. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent herpes simplex infections with oral acyclovir: A controlled trial. JAMA 1984; 251(16):2103-2108.
33. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984; 310:1551-1556.
34. Mertz GJ, Critchlow C, Benedetti J, et al. Double blind placebo-controlled trial of oral acyclovir in first episode genital herpes simplex virus infection. JAMA 1984; 252:1147-1151.
35. Sande M, Armstrong D, Corey L, et al. Perspectives on a switch of oral acyclovir from prescription to OTC status: Report of a consensus panel. Clin Infect Dis.
36. Bryson YJH, Pillon M, Louett M et al. Treatment of first episodes of genital herpes with oral acyclovir. N Engl J Med 1983; 308:916-921.
37. Straus SE, Takiff HE, Seidlu M, et al. Suppression of frequently recurring genital herepes: A placebo conducted double-blind test of oral acyclovir. N Engl J Med 1984; 310:1545-1550.
38. Douglas JM, Davis LG, Remington ML, et al. A double-blind placebo-controlled trial of the effect of chronic oral acyclovir on sperm production in men with frequently recurrent genital herpes. J Infect Dis 1988; 157:588-593.
39. Clive D, Corey L, Reichman RC, Davis LG, Hozier JC. A double-blind, placebo-controlled cytogenetic study of oral acyclovir in patients with recurrent genital herpes. J Infect Dis 1991; 164:753-757.
40. Whitley R, Arvin A, Prober C, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med 1991; 324:444-449.
41. Whitley RJ, Alford CA, Hirsch M, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314:144-149.
42. Centers for Disease Control. 1989 STD treatment guidelines. MMWR 1989; 38(suppl 8):1-43.
43. Coombs RW, Collier AC, Allain J-P, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989; 321: 1626-1631.
44. Volberding PA, Lagakos SW, Koch M, et al. Safety and efficacy of zidovudine in asymptomatic HIV infected individuals with less than 500 CD4 positive cells per cubic millimeter. N Engl J Med 1990; 322:941-949.
45. Collier AC, Bozzette S, Coombs RW, et al. A pilot study of low dose zidovudine therapy in human immunodeficiency virus infection. N Engl J Med 1990; 323:1015-1021.
46. Corey L, Coombs RW. The natural history of HIV infection: implications for assessing antiretroviral therapy. Clin Infect Dis 1993(suppl 1); 16:52-56.
47. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334:1011-1017.
48. Cooney EL, McElrath MJ, Corey L, et al. Enhanced immunity to HIV envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993; 90:1882-1886.
49. Mosier DE, Gulizia RJ, MacIsaac PD, et al. Resistance to HIV infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia-gp160 and recombinant gp160. Proc Natl Acad Sci USA 1993; 90:2443-2447.
50. McElrath MJ, Corey L, Berger D, et al. Immune responses elicited by a recombinant vaccinia-HIV envelope and HIV envelope protein: Analysis of the durability of responses and effect of repeated boosting. J Infect Dis 1994; 169:41-47.
51. Kent SJ, Corey L, Agy MB, Morton WR, McElrath MJ, Greenberg PD. Cytotoxic and proliferative T cell responses in HIV-1 infected M. nemestrina. J Clin Invest 1995; 95:248-256.
52. McElrath MJ, Corey L, Greenberg PD, Matthews TJ, Montefiori DC, Mullins JI. Human immunodeficiency virus type-1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc Natl Acad Sci 1996; 93:3972-3977.
53. Musey L, McElrath JM, Corey L. Envelope cytotoxic T cell responses correlate with viral load and disease progression in early HIV-1 infection. N Engl J Med 1997; 337:1267-1274.
54. Reeves WC, Corey L, Adams HG, Vontver LA, Holmes KK. Risk of recurrence after first episodes of genital herpes: Relation to HSV type and antibody response. N Engl J Med 1981; 305:315-319.
55. Benedetti J, Corey L, Ashley R. Recurrence rates of genital herpes after acquisition of symptomatic first episode infection. Ann Intern Med 1994; 121:847-854.
56. Benedetti JK, Zeh J, Selke S, Corey L. Frequency of reactivation of nongenital lesions among patients with genital herpes simplex virus. Am J Med 1995; 98:237-42.
57. Corey L, Spear PG. Infections with herpes simplex viruses. N Engl J Med 1986(part 1); 314:686-691, (part 2) 314:749-757.
58. Corey L, Spear PG. Infections with herpes simplex viruses. N Engl J Med 1986(part 1); 314:686-691, (part 2) 314:749-757.
59. Koutsky LA, Ashley RL, Holmes KK, et al. The frequency of unrecognized type 2 herpes simplex virus infection among women: Implications for the control of genital herpes. Sex Trans Dis 1990; 17:90-94.
60. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection: Influence of anatomic site and viral type. N Engl J Med 1987; 316:1444-1449.
61. Corey L, Whitley RJ, Stone EF, Mohan K. Difference in neurologic outcome after antiviral therapy of neonatal central nervous system herpes simplex virus type I versus herpes simplex virus type 2 infection. Lancet 1988; 2:1-4.
62. Ashley R, Benedetti J, Corey L. Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. J Med Virol 1985; 17:153-166.
63. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (Immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Micro 1988; 26:662-667.
64. Ashley R, Cent A, Maggs V, Corey L. Inability enzyme immunoassays to discriminate between infections with herpes simplex virus type 1 and 2. Ann Intern Med 1991; 115:520-526.
65. Ashley RL, Wu L, Pickering JW, Tu M-C, Schnorenberg L. Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Micro 1998; 36:294-295.
66. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral isolation procedures. N Engl J Med 1992; 326:1533-1539.
67. Brock BV, Selke S, Benedetti J, Douglas JM, Corey L. Frequency of asymptomatic shedding of HSV in women with genital herpes. JAMA 1990; 263:418-420.
68. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-775.
69. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: Effect of acyclovir treatment. J Clin Invest 1997; 99:1092-1097.
70. Cone RW, Hobson AC, Brown Z, et al. Frequent reactivation of genital herpes simplex viruses among pregnant women. JAMA 1994; 272:792-796.
71. Corey L, Ashley R, Sekulovich A, et al. Lack of efficacy of a vaccine containing recombinant gD2 and gB2 antigens in MF59 adjuvant for the prevention of genital HSV-2 acquisition. Abstract for the 37th ICACC, Toronto, Ontario, Canada, 1997.
72. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" HSV-2 infection. Ann Intern Med 1989; 110:882-887.
73. Mertz GJ, Schmidt O, Jourden J, et al. Frequency of acquisition of first episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Trans Dis 1985; 12:33-39.
74. Wald A, Kim M, Catlett L, Selke S, Ashley R., Corey L. Genital HSV-2 shedding in women with HSV-2 antibodies but without a history of genital herpes. ICAAC abstract, 1996.
75. Wald A, Kim M, Selke S, et al: Recognition of genital lesions in HSV-2 positive person without a history of genital hereps. 10th International Society for STD Research, 1993, Helsinki, Finland.
76. Mertz GJ, Coombs RW, Ashley RL et al. Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: A prospective study. J Infect Dis 1988; 157:1169-1177.
77. Rooney JJ, Felser JM, Ostrove JM, Straus SE. Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med 1986; 314:1561-1564.
78. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991; 324:1247-1252.
79. Brown ZA, Benedetti J, Selke S, Ashley R, Watts DH, Corey L. Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor. Am J Obstet Gynecol 1996; 87:483-88.
80. Moore D, Ashley R, Zarutskie PW, et al. Transmission of genital herpes by donor insemination. JAMA 1989; 261:3441.
81. Mertz GJ, Benedetti J, Ashley R, Selke S, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116:197-202.
82. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124:8-15.
83. Schacker T, Hu H-L, Koelle D, et al. Famciclovir for the suppression of symptomatic and asymptomatic HSV reactivation in HIV-infected persons: A double-blind, placebo-controlled trial. Ann Intern Med (in press).
84. Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex type 2 for Immunotherapy of genital herpes. Lancet 1994; 343:1460-1463.
85. Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial. J Infect Dis 1997; 176:1129-1134.
86. Mertz GJ, Peterman G, Ashley R, et al. Herpes simplex virus type-2 glycoprotein subunit vaccine: Tolerance and humoral and cellular immune responses in humans. J Infec Dis 1984; 150:242-249.
87. Ashley R, Mertz G, Clark H, Schick M, Salter D, Corey L. Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine. J Virol 1985; 56:475-481.
88. Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type-2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990; 161:653-660.
89. Langenberg AGM, Burke RL, Adair S, Sekulovich R, Dekker C, Corey L. A recombinant glycoprotein vaccine for herpes simplex type 2: Safety and immunogenicity. Ann Intern Med 1995; 122:889-898.
90. Posavad C, Koelle DM, Corey L. High frequency of CD8+ cytotoxic T lymphocyte precursors specific for herpes simplex virus type 2 in patients with genital herpes. J Virol 1996; 70:8165-8168.
91. Koelle DM, Abbo H, Peck A, Ziegweid K, Corey L. Direct recovery of HSV-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis 1994; 169:956-961.
92. Tigges MA, Koelle D, Hartog K, Sekulovich RE, Corey L, Burke RL. Human CD8+ herpes simplex virus-specific cytotoxic T lymphocyte clones recognize diverse virion protein antigens. J Virol 1992; 66:1622-1634.
93. Posavad CM, Koelle DM, Shaughnessy MF, Corey L. Severe genital herpes infections in HIV-infected individuals with impaired HSV-specific CD8+ CTL responses. Proc National Acad Sci USA 1997; 94:10289-10294.
94. Koelle DM, Corey L, Burke RL, Eisenberg RJ, Cohen GH, Pichyangkura R, Triezenberg SJ. 1994 Antigenic specificities of human CD4+ T cell clones recovered from recurrent genital HSV-2 lesions. J Virol 1998; 68:2803-2810.
95. Fleming DT, McQuillan GM, Johnson RE, et al: Herpes simplex virus type 2 in the United States, 1976 - 1994. N Engl J Med 1997; 337:1105-1111.
96. Parran T. Shadow on the Land. Baltimore, MD: Waverly Press, 1937:237.
97. Parran T. Shadow on the Land. Baltimore, MD: Waverly Press, 1937:77.
98. Klovdahl A. Social networks and the spread of infectious disease: the AIDS example. Soc Sci Med 1985; 21:1203-1216.
99. Greenblat R, Lukehart S, Plummer F, et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 1988; 2:47-50.
100. Stamm W, Handsfield H, Rompalo A, Ashley R, Roberts P, Corey L. Association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988; 260:1429-1433.
101. Keet I, Lee F, van Griensven G, Lange J, Nahmias A, Coutinho R. Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition. Genitourin Med 1990; 66:330-333.
102. Boulos R, Ruff A, Nahmias A, et al. The Johns Hopkins University (JHU)/Centre pour le Development et al, Sante (CDS) HIV Study Group. Herpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human T lymphotropic virus type 1 infections. J Infect Dis 1992; 166:418-420.
103. Hook E, Canon R, Nahmias A, Lee F, Campbell J, Classer D, Quinn T. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis 1992; 165:251-255.
104. Telzak E, Chaisson A, Bevier P, Stoneburner R, Castro K, Jaffe H. HIV-1 seroconversion in patients with and without genital ulcer disease. Ann Intern Med 1993; 119:1181-1186.
105. Dickerson M, Johnston J, Delea T, White A, Andrews E. The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus: an application of the Bradford Hill criteria. Sex Trans Dis 1996; 23:429-440.
106. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1. Lancet 1997; 349:1868-1873.
107. Lee FK, Coleman RM, Pereira L, Bailey PD, Tatsuno M, Nahmias AJ. Detection of hereps simplex virus type 2-specific antibody with glycoprotein G. J Clin Micro 1985; 22:642-644.
108. Schachter J, Moncada J, Whidden R, et al. Noninvasive tests for diagnosis of chlamydia trachomatis infection: Application of ligase chain reaction to first-catch urine specimens of women. J infect Dis 1995; 172:1411-1414.
109. Schachter J, Stamm WE, Quinn TC, Andrews WW, Burczak JD, Lee HH. Ligase chain reaction to detect chlamydia trachomatis infection of the cervix. J Clin Microbiol 1994; 32:2540-2543.
110. Corey L. The current trend in genital herpes. Progress in prevention. Sex Trans Dis 1994; 21(suppl 2):S38-S44.
111. Prober CG, Corey L, Brown ZA, et al. A consensus on the management of pregnant women with genital herpes simplex virus infection. Clin Infect Dis 1992; 15:1031-1038.
112. Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AS, Arvin AM. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent herpes simplex virus infections. N Engl J Med 1987; 316:;240-244.
113. Kulhansian JA, Soroush V, Au DS, et al. Identification of women at unsuspected risk of primary infection with HSV-2 during pregnancy. N Engl J Med 1992; 236:916-920.
114. Klumneck N, Taelman H, Hermans P, Piot P, Schoumacher M, DeWit S. A cluster of HIV infection among heterosexual people without apparent risk factors. N Engl J Med 1989; 321:1460-1462.
115. Kreiss J, Coombs R, Plummer F, et al. Isolation of human immunodeficiency virus from genital ulcers in Nairobi Prostitutes. J Infect Dis 1989; 160:380-384.
116. Higgins D, Galavotti C, O'Reilly K, Shcnell D, Moore M, Rugg D, Johnson R. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA 1991; 266:2419-2429.
117. Fox R, Odaka N, Brookmeyer R, Polk B. Effect of HIV antibody disclosure on subsequent sexual activity in homosexual men. Gower Academic J 1987; 1:241-246.
118. Allen S, Serufilira A, Bogaerts J, et al. Confidential HIV testing and condom promotion in Africa. JAMA 1992; 268:3338-3343.
119. Otten M, Zaidi A, Wroten J, Witte J, Peterman T. Changes in sexually transmitted disease rates after HIV testing and posttest counseling, Miami 1988 to 1989. Am J Pub Health 1993; 83:529-533.
120. Parran T. Shadow on the Land. Baltimore, MD: Waverly Press, 1937:132.
121. Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after first episode of genital herpes. Ann Intern Med 1992; 116:433-437.
122. Parran T. Shadow on the Land. Baltimore, MD: Waverly Press, 1937:88, 132.